Clinical Trials Directory

Trials / Unknown

UnknownNCT04961060

Drivers of Eosinophilic COPD Exacerbations

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes.

Detailed description

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes to better understand why some patients are more at risk for eosinophilic COPD exacerbations. Secondary objectives: 1. Investigate differences in microbiome composition and immunophenotyping profiles in peripheral blood per subtype. 2. Assess for clinical differences between all COPD exacerbation subtypes. 3. Assess if and how baseline meta-transcriptomics either in nasal epithelium or sputum and blood immunophenotyping can be utilized to predict COPD exacerbation subtype. 4. Determine if the microbiome in sputum and nasal epithelial material are comparable. 5. Determine if different subtypes of COPD exacerbations respond differently to standard treatment with oral prednisolone (40 mg daily) with or without antibiotics. 6. To evaluate if metabolic responses during recovery are different in patients with increased systemic inflammation compared to patients without systemic inflammation at exacerbation

Conditions

Timeline

Start date
2021-07-01
Primary completion
2024-09-01
Completion
2025-01-01
First posted
2021-07-14
Last updated
2021-07-14

Locations

2 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04961060. Inclusion in this directory is not an endorsement.

Drivers of Eosinophilic COPD Exacerbations (NCT04961060) · Clinical Trials Directory